4P004
Knee Osteoarthritis
Key Facts
About 4Moving Biotech
4Moving Biotech is a French biotech founded in 2017, focused on developing first-in-class disease-modifying osteoarthritis drugs (DMOADs). Its lead program, 4P004, a GLP-1 analog, has completed Phase 1 and entered a Phase 2a proof-of-concept study, supported by a €12 million financing round in early 2026. The company employs a distinctive strategy integrating AI-driven in-silico trials and analysis of large-scale patient data to de-risk and accelerate clinical development in the vast, underserved osteoarthritis market.
View full company profileAbout 4P-Pharma
4P-Pharma is a Lille-based biotech leveraging an innovative partnership and Single Product Vehicle (SPV) model to de-risk and accelerate drug development. Its pipeline includes a Phase II asset for osteoarthritis and a discovery program for primary sclerosing cholangitis, targeting large and rare disease markets, respectively. The company combines in-house CRO-like expertise with open innovation sourcing, has raised over €20M, and operates with a team of 25+ across two sites in France.
View full company profileTherapeutic Areas
Other Knee Osteoarthritis Drugs
| Drug | Company | Phase |
|---|---|---|
| Progenza | Cambium Bio | Phase 1/2a |
| MAG200 | Magellan | Phase 3 |
| MUTI™ Knee Replacement | Meril | Commercial |
| DUROLANE | Bioventus | Commercial |
| XSTEM | Xintela | Phase I/IIa |
| Stempeucel® | Stempeutics Research | Commercial |
| Lipogems System for Knee Osteoarthritis | Lipogems International | Phase 3 |
| Signature Cord Prime™ | Arugula Sciences | Phase 1 |
| Knee Osteoarthritis Study | Arizona Research Center | Not Specified |
| Lorecivivint (inferred) | Biosplice Therapeutics | Phase 3 |
| Regenerative Cell Therapy for Osteoarthritis | InGeneron | Phase 3 |
| ArthroCart | Arthro Biotech | Preclinical |